Navigating The Future Of Biotech Key Insights From Ey S Linkedin

Bonisiwe Shabane

-Nov 29, 2025, 9:18 PM

navigating the future of biotech key insights from ey s linkedin

The biotech industry stands at a crossroads, poised for a transformative era characterized by rapid innovation and significant financial challenges. The latest EY "Beyond Borders 2024" report provides a comprehensive overview of the trends, challenges, and opportunities that will shape the future of the biotech sector. Here’s a deep dive into the key insights that every biotech leader should know: Despite recent financial challenges, biotech innovation is robust, driven by advancements in new therapeutic modalities and emerging technologies like AI and machine learning. The report highlights a notable shift towards revitalizing areas such as chronic diseases, which had previously fallen out of favor. This resurgence is fueling the development of new treatments for conditions affecting large patient populations, such as diabetes, obesity, and mental health disorders.

Key Insight: Innovation in biotech is not slowing down. Companies are increasingly focusing on leveraging cutting-edge technologies to bring novel therapies to market, ensuring long-term growth and impact. The report paints a complex picture of the biotech financing landscape. While companies with late-stage assets are securing substantial investments, early-stage biotechs are struggling to attract funding. This disparity underscores the need for emerging biotechs to adopt strategic financial planning and operational efficiency to survive and thrive. Key Insight: Biotech firms must focus on building robust financial strategies, emphasizing capital efficiency and cost management to navigate the current challenging financing environment.

#Biotech2024 #Innovation #Sustainability #DigitalTransformation #MergersAndAcquisitions #Financing #RegulatoryCompliance #LifeSciences 🌍💊 Biotech Beyond Borders: Redefining the Future in 2025 Biotech is no longer confined by geography. In 2025, the sector is being reshaped by global market shifts, new funding realities, and the power of cross-border partnerships. EY’s latest Biotech Outlook Report makes one thing clear: the companies that will thrive are those that think globally, move fast on capital strategy, and build smart collaborations that cut across traditional boundaries. From market outlooks to funding flows and partnering insights, this report maps the opportunities (and challenges) that will define biotech’s next chapter. The question is-who’s ready to lead?

👉 Read the full report here: https://lnkd.in/gzqD9FD8 #Biotech #LifeSciences #BiotechOutlook #HealthcareInnovation #Pharma #DrugDiscovery #FutureOfHealth #BiotechFunding #GlobalBiotech #Innovation Biotech firms increasingly face a squeeze: rising costs, tighter capital, and shifting regulatory expectations. Our latest piece delves into how these pressures are reshaping research models, partnerships, and internal strategy across the industry. Learn how organizations are adapting and where innovation might emerge next. 🔗 https://lnkd.in/gy_3v7D2 #Biopharma #R&DStrategy #IndustryTrends Fewer deals.

Higher stakes. Biopharma dealmaking is shifting in 2025. According to McKinsey, there are fewer deals overall, but the ones that do occur are more selective, often focusing on late-stage assets with proven potential. Here are some key takeaways: ✔️ Deal values are rising even as volumes fall. ✔️ Clinical and late-stage programs are winning attention over early, riskier bets. ✔️ Economic and geopolitical pressures are forcing smarter, more strategic choices.

This essentially means prioritizing quality over quantity. Companies need rigorous evaluation frameworks and speed paired with scientific confidence to capture the right opportunities. How is your team adjusting its dealmaking strategy this year? Leaning later-stage or still betting on early innovation? Read the full McKinsey piece here: https://lnkd.in/dxRrrWB5 #Biopharma #DealMaking #ExternalInnovation #PharmaStrategy #DrugDevelopment Valuing Pharma & Life Sciences 💊🧬 Drug discovery is capital-intensive, uncertain, and time-bound.

How do we price innovation that might take a decade to pay off? 📌 Key Drivers ✔ Patent Life & Exclusivity – Determines DCF horizon. ✔ R&D Pipeline – Probability-weighted outcomes matter. ✔ Regulatory Approval – FDA/EMA timelines shape value. 📊 Approaches ✅ Probability-Adjusted DCF – Based on success rates by phase. ✅ Option Pricing – Valuing potential molecule success.

✅ Market Comparables – Benchmarking biotech peers. 🚀 Way Forward: ✔ Blend science with finance. ✔ Recognize IP as core asset. ✔ Integrate ESG and social impact metrics. 📢 Should R&D be expensed or capitalized? The debate continues.

👇 #PharmaValuation #LifeSciences #IntangibleAssets #BusinessValuation Biotech deals are being made, a possible signal that valuations have become attractive - a good sign for investor interest at all stages of development. (Reference: https://lnkd.in/eAPxH3Sx ) EY helps clients create long-term value for all stakeholders. Enabled by data and technology, our services and solutions provide trust through assurance and help clients transform, grow and operate. Discover how EY insights and services are helping to reframe the future of your industry.

How digital twin technology powers the future at Xcel Energy How Bristol Myers Squibb overhauled working capital to fund its future How St James’s Hospital's journey to cloud transformed cancer care After 34 years, the EY Beyond Borders Biotech Report continues to deliver key insights and analysis that the entire life sciences sector waits for. This is a 'must-read' for all life sciences executives, board members and investors. [LAUNCHED] 34th edition of our flagship biotech report.

👇 https://go.ey.com/4bGMTfH Join Arda Ural, MSc, MBA, PhD at #BIO2024 to learn how the biotech industry is well positioned for a comeback when the financing environment improves. 📊 The 35th annual EY Biotech Beyond Borders report delves into the transformative changes shaping the #biopharma sector. It explores how these shifts impact the industry and outlines strategies for achieving long-term success amid ongoing uncertainty. Dive into the insights and access the report here: https://ow.ly/fQMJ30sPPgi #EYCanada #ShapeTheFutureWithConfidence 📊 The 35th annual EY Biotech Beyond Borders report delves into the transformative changes shaping the #biopharma sector. It explores how these shifts impact the industry and outlines strategies for achieving long-term success amid ongoing uncertainty.

Dive into the insights and access the report here: https://ow.ly/XZ1A30sPNWN #EYCanada #ShapeTheFutureWithConfidence 📊 The 35th annual EY Biotech Beyond Borders report delves into the transformative changes shaping the #biopharma sector. It explores how these shifts impact the industry and outlines strategies for achieving long-term success amid ongoing uncertainty. Dive into the insights and access the report here: https://ow.ly/vKXC30sPQ9T #EYCanada #ShapeTheFutureWithConfidence 📊 The 35th annual EY Biotech Beyond Borders report delves into the transformative changes shaping the #biopharma sector. It explores how these shifts impact the industry and outlines strategies for achieving long-term success amid ongoing uncertainty.

Dive into the insights and access the report here: https://ow.ly/Frea30sPNLn #EYCanada #ShapeTheFutureWithConfidence Just read Blue Matter’s 1H 2025 biopharma deal analysis. Fewer big-ticket acquisitions, more strategic partnerships. Oncology still leads, but rare diseases and CGTs are quietly gaining momentum. Licensing is outpacing M&A. Smart capital, cautious optimism.

My take: we’re stress-testing innovation models in real time. The winners will be the ones who balance risk, runway, and relevance. #Biopharma #HealthcareStrategy #LifeSciences #DrugPricing #LicensingDeals I'm pleased to share the 33rd edition of our annual Beyond Borders: EY biotechnology report. After incredible growth in 2021 and a slower 2022, the biotech industry now finds itself navigating a complex path forward. With deep insights from EY thought leaders and perspectives from industry executives on tax compliance and operating models, digitalization, capital constraints and other top-of-mind issues, our analysis of the state of the industry leaves...

Especially proud of our tax insights around tax transformation and a big thanks to Peter Schreiner at Novartis for his invaluable contributions! Check out the full report: ey.com/beyond-borders. #tax #operatingmodel #taxtransformation Dave Helmer Today, at #BIO2023, I'll present the 33rd edition of our Beyond Borders: EY biotechnology report. As #biotech continues to pivot from incredible growth in 2021 and a more normalized 2022, the report provides a deep dive into the state of the biotech industry and its financial performance, deal environment... We're pleased to have several guest perspectives from industry leaders and investors on an array of key topics, including digitalization, capital allocation and tax compliance.

Check out the full report: ey.com/beyond-borders. Special thanks to Richard Ramko, Ashwin Singhania, Duane Van Arsdale, Lorence Kim, Jeffrey Tong, Andrew Hack, MD, PhD, Anthony Mancini and Peter Schreiner. Multi Cloud Senior Solutions Architect || Ex Kyndryl | IBM | Deloitte | IQVIA | ARIS Global | Bioclinica | GenAI - JLPT N2, CISM, PMP, Togaf 10 Excellent report! The insights on tax compliance, digitalization and operating models provide a comprehensive understanding of the challenges and opportunities faced by the biotech industry. EY helps clients create long-term value for all stakeholders.

Enabled by data and technology, our services and solutions provide trust through assurance and help clients transform, grow and operate. Discover how EY insights and services are helping to reframe the future of your industry. How digital twin technology powers the future at Xcel Energy How Bristol Myers Squibb overhauled working capital to fund its future How St James’s Hospital's journey to cloud transformed cancer care Pleased to share the latest edition of the annual Beyond Borders: EY biotechnology report.

Navigating The Future Of Biotech Key Insights From Ey S Linkedin

People Also Search

The Biotech Industry Stands At A Crossroads, Poised For A

Key Insight: Innovation In Biotech Is Not Slowing Down. Companies

#Biotech2024 #Innovation #Sustainability #DigitalTransformation #MergersAndAcquisitions #Financing #RegulatoryCompliance #LifeSciences 🌍💊 Biotech

👉 Read The Full Report Here: Https://lnkd.in/gzqD9FD8 #Biotech #LifeSciences #BiotechOutlook

Higher Stakes. Biopharma Dealmaking Is Shifting In 2025. According To